Search

Your search keyword '"Lin, Xiaoyan"' showing total 1,799 results
Start Over Author "Lin, Xiaoyan"
1,799 results on '"Lin, Xiaoyan"'

4. The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.

Author

Jiang, Xiaoyu, Wang, Yuli, Guo, Lulu, Wang, Yige, Miao, Tianshu, Ma, Lijuan, Wei, Qin, Lin, Xiaoyan, Mao, Jian-Hua, and Zhang, Pengju

Subjects
Breast cancer, Chemotherapy, FAM83D, FBXW7, Metastasis, Ubiquitination and degradation, Humans, Female, F-Box-WD Repeat-Containing Protein 7, Cell Cycle Proteins, Cell Line, Tumor, Breast Neoplasms, Prognosis, Cell Proliferation, Gene Expression Regulation, Neoplastic, Microtubule-Associated Proteins
Abstract

Increasing evidence shows the oncogenic function of FAM83D in human cancer, but how FAM83D exerts its oncogenic function remains largely unclear. Here, we investigated the importance of FAM83D/FBXW7 interaction in breast cancer (BC). We systematically mapped the FBXW7-binding sites on FAM83D through a comprehensive mutational analysis together with co-immunoprecipitation assay. Mutations at the FBXW7-binding sites on FAM83D led to that FAM83D lost its capability to promote the ubiquitination and proteasomal degradation of FBXW7; cell proliferation, migration, and invasion in vitro; and tumor growth and metastasis in vivo, indicating that the FBXW7-binding sites on FAM83D are essential for its oncogenic functions. A meta-evaluation of FAM83D revealed that the prognostic impact of FAM83D was independent on molecular subtypes. The higher expression of FAM83D has poorer prognosis. Moreover, high expression of FAM83D confers resistance to chemotherapy in BCs, which is experimentally validated in vitro. We conclude that identification of FBXW7-binding sites on FAM83D not only reveals the importance for FAM83D oncogenic function, but also provides valuable insights for drug target.

Published
2024

5. Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial

Author

Yang, Jing, Weng, Lizhu, Chen, Zhikui, Cai, Hongfu, Lin, Xiaoyan, Hu, Zhijian, Li, Na, Lin, Bijuan, Zheng, Bin, Zhuang, Qian, Du, Bin, Zheng, Zhiyuan, and Liu, Maobai

Subjects
Information technology, T58.5-58.64, Public aspects of medicine, RA1-1270
Abstract

BackgroundThe incidence of cancer pain increases in discharged patients because of discontinued standard treatments and reductions in medication adherence. Motivated by the need for better pain management in discharged patients, we developed a mobile phone app (Pain Guard) to provide continuous treatment information and feedback to discharged cancer patients suffering from pain. ObjectiveThe aim was to design, construct, and test the Pain Guard app in patients managing cancer pain, evaluate the total remission rate of pain and the improvement in quality of life (QoL) to improve pain management for cancer pain patients, and assess patient acceptance of the app. MethodsThis randomized controlled double-arm study involved 58 patients with cancer pain symptoms. Participants were randomly assigned to a group receiving care through the Pain Guard app (n=31) or to a control group (n=27) who received only traditional pharmaceutical care. In a pretest, participants were rated using a baseline cancer pain assessment and QoL evaluation. During treatment, the consumption levels of analgesic drugs were recorded every week. After a 4-week study period, another round of cancer pain assessment and QoL evaluation was conducted. The system’s usability, feasibility, app compliance, and satisfaction were also assessed. Our primary outcome was remission rate of pain, and secondary outcomes were medication adherence, improvements in QoL, frequency of breakthrough cancer pain (BTcP), incidence of adverse reactions, and satisfaction of patients. ResultsAll participants (N=58) successfully completed the study. There were no significant differences in baseline pain scores or baseline QoL scores between groups. At the end of the study, the rate of pain remission in the trial group was significantly higher than that in the control group (P

Published
2019
Full Text
View/download PDF

6. Exosome is a Fancy Mobile Sower of Ferroptosis

Author

Hou, Qin, Ouyang, Siyu, Xie, Zhongcheng, He, Yinling, Deng, Yunong, Guo, Jiamin, Yu, Panpan, Tan, Xiaoqian, Ma, Wentao, Li, Pin, Yu, Jiang, Mo, Qinger, Zhang, Zhixia, Chen, Dandan, Lin, Xiaoyan, Liu, Zhiyang, Chen, Xi, Peng, Tianhong, Li, Liang, and Xie, Wei

Published
2024
Full Text
View/download PDF

8. The dual role of FSP1 in programmed cell death: resisting ferroptosis in the cell membrane and promoting necroptosis in the nucleus of THP-1 cells

Author

Tan, Xiaoqian, He, Yinling, Yu, Panpan, Deng, Yunong, Xie, Zhongcheng, Guo, Jiami, Hou, Qin, Li, Pin, Lin, Xiaoyan, Ouyang, Siyu, Ma, Wentao, Xie, Yushu, Guo, Zilong, Chen, Dandan, Zhang, Zhixia, Zhu, Yunyu, Huang, Fei, Zhao, Ziye, Zhang, Cen, Guo, Zhirong, Chen, Xi, Peng, Tianhong, Li, Liang, and Xie, Wei

Published
2024
Full Text
View/download PDF

9. Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study

Author

Chen, Xiaozhong, Wang, Wei, Zou, Qingfeng, Zhu, Xiaodong, Lin, Qin, Jiang, Yi, Sun, Yan, Shen, Liangfang, Wang, Lin, Zou, Guorong, Lin, Xiaoyan, Lin, Shaojun, Li, Minying, Wang, Ying, Xu, Ruilian, Ao, Rui, Wang, Rensheng, Lin, Haifeng, Huang, Shuang, Xu, Tingting, Li, Wenting, Xia, Mengying, Xia, Yu, Wang, Zhongmin, Li, Baiyong, Li, Jingao, and Hu, Chaosu

Published
2024
Full Text
View/download PDF

12. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

Author

Li, Jin, Bai, Yuxian, Chen, Zhendong, Ying, Jieer, Guo, Yabing, Fang, Weijia, Zhang, Feng, Xiong, Jianping, Zhang, Tao, Meng, Zhiqiang, Zhang, Jingdong, Ren, Zhenggang, Hao, Chunyi, Chen, Yajin, Lin, Xiaoyan, Pan, Hongming, Zhou, Fuxiang, Li, Xin, Yu, Fan, Zhang, Juan, Zhang, Zhang, and Qin, Shukui

Published
2024
Full Text
View/download PDF

17. Mountain-pass-type solutions for Schrödinger equations in R2 with unbounded or vanishing potentials and critical exponential growth nonlinearities

Author

Lin Xiaoyan, Tang Xianhua, and Zhang Ning

Subjects
schrödinger equations, critical exponential growth, trudinger-moser inequality, mountain-pass-type solution, 35j20, 58e50, Analysis, QA299.6-433
Abstract

In this article, we consider the existence of solutions for nonlinear elliptic equations of the form −Δu+V(∣x∣)u=Q(∣x∣)f(u),x∈R2,-\Delta u+V\left(| x| )u=Q\left(| x| )f\left(u),\hspace{1em}x\in {{\mathbb{R}}}^{2}, where the nonlinear term f(s)f\left(s) has critical exponential growth which behaves like eαs2{e}^{\alpha {s}^{2}}, the radial potentials V,Q:R+→RV,Q:{{\mathbb{R}}}^{+}\to {\mathbb{R}} are unbounded, singular at the origin or decaying to zero at infinity. By combining the variational methods, Trudinger-Moser inequality, and some new approaches to estimate precisely the minimax level of the energy functional, we prove the existence of a Mountain-pass-type solution for the above problem under some weak assumptions.

Published
2024
Full Text
View/download PDF

18. Upregulation of WDR6 drives hepatic de novo lipogenesis in insulin resistance in mice

Author

Yao, Zhenyu, Gong, Ying, Chen, Wenbin, Shao, Shanshan, Song, Yongfeng, Guo, Honglin, Li, Qihang, Liu, Sijin, Wang, Ximing, Zhang, Zhenhai, Wang, Qian, Xu, Yunyun, Wu, Yingjie, Wan, Qiang, Zhao, Xinya, Xuan, Qiuhui, Wang, Dawei, Lin, Xiaoyan, Xu, Jiawen, Liu, Jun, Proud, Christopher G., Wang, Xuemin, Yang, Rui, Fu, Lili, Niu, Shaona, Kong, Junjie, Gao, Ling, Bo, Tao, and Zhao, Jiajun

Published
2023
Full Text
View/download PDF

28. Introduction

Author

Lin, Xiaoyan, Li, Yang, Series Editor, Li, Peilin, Series Editor, Lin, Xiaoyan, Chen, Yanqing, Translated by, and Zhu, Yuntao, Translated by

Published
2023
Full Text
View/download PDF

38. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study

Author

Zheng, Xinlong, Zhang, Longfeng, Wu, Lin, Zhao, Jun, Sun, Jianguo, Fang, Yong, Zhou, Jin, Chu, Qian, Shen, Yihong, Yang, Zhenzhou, Chen, Lijin, Huang, Meijuan, Lin, Xiaoyan, Liu, Zhenhua, Shen, Peng, Wang, Zhijie, Wang, Xin, Wang, Huijuan, Han, Zhengbo, Liu, Anwen, Zhang, Hongmei, Ye, Feng, Gao, Wen, Wu, Fang, Song, Zhengbo, Chen, Shengchi, Zhou, Chenzhi, Wang, Qian, Xu, Chunwei, Huang, Dingzhi, Zheng, Xiaobin, Miao, Qian, Jiang, Kan, Xu, Yiquan, Wu, Shiwen, Wang, Haibo, Zhang, Qiuyu, Yang, Shanshan, Li, Yujing, Chen, Sihui, and Lin, Gen

Published
2023
Full Text
View/download PDF

39. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

Author

Li, Jin, Qin, Shukui, Wen, Lu, Wang, Junsheng, Deng, Wenying, Guo, Weijian, Jia, Tongfu, Jiang, Da, Zhang, Guifang, He, Yifu, Ba, Yi, Zhong, Haijun, Wang, Lin, Lin, Xiaoyan, Yang, Jianwei, Zhao, Jun, Bai, Yuxian, Wu, Xiangyuan, Gao, Feng, Sun, Guogui, Wu, Yongjuan, Ye, Feng, Wang, Qiong, Xie, Zhong, Yi, Tienan, Huang, Yong, Yu, Guohua, Lu, Lin, Yuan, Ying, Li, Wei, Liu, Likun, Sun, Yuping, Sun, Ying, Yin, Lifeng, and Hou, Zhiguo

Published
2023
Full Text
View/download PDF

49. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Author

Mendez, Guillermo, O'Connor, Juan Manuel, Yanzi Castilla, Alvaro, Cundom, Juan, Kaen, Diego, Wong, Rachel, Ng, Weng, Aghmesheh, Morteza, Peressoni, Mauricio, Andrade, Carlos, Franke, Fabio, Alves, Gustavo, Cruz, Felipe Jose, Vianna, Karina, Monteiro, Maria Marcela, Raphael, Michael, Berry, Scott, Jang, Raymond, Tan, Ann, Asselah, Jamil, Yanez Weber, Patricio, Mahave, Mauricio, Sanchez, Cesar, Salman, Pamela, Bai, Yuxian, Li, Jin, Zhang, Xiaochun, Liu, Tianshu, Lin, Xiaoyan, Qin, Shukui, Yang, Jianwei, Luo, Suxia, Li, Wei, Ying, Jieer, Chen, Xi, Zeng, Shan, Qu, Yanli, Yang, Lin, Zhao, Lin, Chen, Ping, Pan, Hongming, Li, Enxiao, Ye, Feng, Lu, Jianwei, Liang, Xinjun, Zhao, Qun, Yin, Xianli, Li, Junhe, Ling, Yang, Lv, Guoqing, Li, Shouguo, Guerrero, Alvaro, Rubiano, Juan, Gonzalez Fernandez, Manuel, Manneh Kopp, Ray, Guzman Ramirez, Adrian, Corrales, Luis, Gonzalez Herrera, Ileana, Melichar, Bohuslav, Buchler, Tomas, Svoboda, Tomas, Obermannova, Radka, Vrana, David, Cvek, Jakub, Pfeiffer, Per, Baeksgaard, Lene, Yilmaz, Mette, Boige, Valerie, Lopez-Trabada, Daniel, Borg, Christophe, Pannier, Diane, Hiret, Sandrine, Di Fiore, Frederic, Metges, Jean-Philippe, Arnold, Dirk, Martens, Uwe, Lordick, Florian, Stein, Alexander, Castro, Hugo, Lopez, Karla, Ramirez, Julio, Aguilar, Mynor, Chivalan, Marco, Chan, Wendy, Cheng, Ashley, Yeo, Winnie, Arkosy, Peter, Csoszi, Tibor, Hitre, Erika, Horvath, Zsolt, Lowery, Maeve, McDermott, Ray, Morris, Patrick, Hubert, Ayala, Brenner, Baruch, Ben-Aharon, Irit, Shacham-Shmueli, Einat, Man, Sofia, Pelles Avraham, Sharon, Brenner, Ronen, Mishaeli, Moshe, Di Bartolomeo, Maria, Fazio, Nicola, Lonardi, Sara, Garufi, Carlo, Satoh, Taroh, Hara, Hiroki, Iwagami, Shiro, Yasui, Hisateru, Tsuda, Masahiro, Shimoyama, Tatsu, Shoji, Hirokazu, Sugimoto, Naotoshi, Shibata, Nobuhiro, Yamaguchi, Kensei, Amagai, Kenji, Choda, Yasuhiro, Esaki, Taito, Yabusaki, Hiroshi, Oshima, Takashi, Tsuji, Akihito, Kawakami, Hisato, Kawazoe, Akihito, Ishido, Kenji, Kadowaki, Shigenori, Martinez Rodriguez, Jorge, Herrera Martinez, Marytere, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Balancan, Paola, Damianovich, Dragan, Castro Oliden, Victor, Grados, Julio, Torres, Cesar, Wyrwicz, Lucjan, Wysocki, Piotr, Hajac, Lukasz, Zolnierek, Jakub, Karaszewska, Boguslawa, Rha, Sun Young, Lee, Jeeyun, Ryu, Min-Hee, Oh, Do-Youn, Orlova, Rashida, Tjulandin, Sergey, Fadeeva, Natalia, Makarycheva, Yulia, Nosov, Dmitry, Smagina, Maria, Chan, Sze, Jacobs, Conrad, Kraus, Peter, Landers, Gregory, Robertson, Barbara, Ruff, Paul, Schoeman, Elizabeth, Maurel, Jean-Marc, Diez Garcia, Marc, Jimenez Fonseca, Paula, Gallego Plazas, Javier, Rivera Herrero, Fernando, Miranda Poma, Jesus, Layos Romero, Laura, Fritsch, Ralph, Bastian, Sara, Winterhalder, Ralph, Dosso, Sara De, Kossler, Thibaud, Yeh, Kun-Huei, Yen, Chia-Jui, Chen, Yen-Yang, Lin, Johnson, Bilici, Mehmet, Ozguroglu, Mustafa, Cil, Timucin, Oksuzoglu, Berna, Harputluoglu, Hakan, Karaoglu, Aziz, Hacibekiroglu, Ilhan, Erdogan, Bulent, Yalcin, Suayib, Adamchuk, Hryhoriy, Bondarenko, Igor, Kolesnik, Oleksii, Ostapenko, Yuriy, Kryzhanivska, Anna, Leshchenko, Lurii, Ilin, Ievgen, Shparyk, Yaroslav, Trukhin, Dmytro, Voitko, Nataliia, Roy, Rajarshi, Young, Anna-Mary, Medley, Louise, Shiu, Kai-Keen, Celano, Paul, Overton, Lindsay, Raj, Moses, Dunne, Richard, Wainberg, Zev, Dayyani, Farshid, Larson, Timothy, Kochenderfer, Mark, Yañez, Patricio, Rivera, Fernando, Alves, Gustavo Vasconcelos, Garrido, Marcelo, Fernández, Manuel González, Lowery, Maeve A, Çil, Timuçin, Cruz, Felipe Melo, Wainberg, Zev A, Yin, Lina, Bordia, Sonal, Bhagia, Pooja, and Wyrwicz, Lucjan S

Published
2023
Full Text
View/download PDF

50. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Author

Gao, Xiangyu, Xu, Nong, Li, Ziyu, Shen, Lin, Ji, Ke, Zheng, Zhong, Liu, Dan, Lou, Hanmei, Bai, Li, Liu, Tianshu, Li, Yunxia, Li, Yuzhi, Fan, Qingxia, Feng, Mei, Zhong, Haijun, Huang, Yi, Lou, Ge, Wang, Jing, Lin, Xiaoyan, Chen, Ye, An, Ruifang, Li, Changzheng, Zhou, Qi, Huang, Xin, Guo, Zengqing, Wang, Shubin, Li, Guiling, Fei, Junwei, Zhu, Lijing, Zhu, Hong, Li, Xiumin, Li, Fenghu, Liao, Sihai, Min, Qinghua, Tang, Lei, Shan, Fei, Gong, Jifang, Gao, Yunong, Zhou, Jun, Lu, Zhihao, Li, Xiaofan, Li, Jianjie, Ren, Hui, Liu, Xiaohong, Yang, Hongxia, Li, Wenting, Song, Weifeng, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Michelle, Wu, Xiaohua, and Ji, Jiafu

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results